Personalis (NASDAQ:PSNL) Hits New 1-Year High – Time to Buy?

Shares of Personalis, Inc. (NASDAQ:PSNL) reached a new 52-week high on Tuesday . The company traded as high as $10.95 and last traded at $10.12, with a volume of 2479778 shares changing hands. The stock had previously closed at $9.13.

Analyst Ratings Changes

A number of research firms have weighed in on PSNL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a report on Wednesday, October 8th. Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. HC Wainwright reaffirmed a “buy” rating and set a $8.50 target price on shares of Personalis in a report on Monday, September 8th. Finally, BTIG Research lifted their target price on Personalis from $6.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Personalis has an average rating of “Moderate Buy” and an average target price of $8.25.

Personalis Stock Performance

The stock has a 50-day moving average of $6.33 and a two-hundred day moving average of $5.56. The company has a market cap of $791.91 million, a P/E ratio of -6.98 and a beta of 1.83.

Personalis (NASDAQ:PSNL) last released its earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. The company had revenue of $17.20 million during the quarter, compared to the consensus estimate of $20.12 million. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts forecast that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Institutional Trading of Personalis

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Farther Finance Advisors LLC bought a new stake in Personalis in the third quarter valued at approximately $66,000. Howland Capital Management LLC lifted its position in Personalis by 0.9% in the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock valued at $1,872,000 after purchasing an additional 2,500 shares during the last quarter. Man Group plc bought a new stake in Personalis in the second quarter valued at approximately $324,000. BNP Paribas Financial Markets lifted its position in Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Personalis by 10.5% in the second quarter. Bank of America Corp DE now owns 222,011 shares of the company’s stock valued at $1,456,000 after purchasing an additional 21,009 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.